Coronary heart disease

CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population

Y. M. Guo, Zhao, Z. C., Zhang, L., Li, H. Z., Li, Z., Sun, H. L., Guo, Y. M., Zhao, Z. C., Zhang, L., Li, H. Z., Li, Z., and Sun, H. L., “CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population”, vol. 15, p. -, 2016.

The goal of this study was to explore the polymorphisms of CYP2C19 (CYP2C19*2, CYP2C19*3) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) on clopidogrel therapy in Zhengzhou city for guidance on clinical medication and reduction in the incidence of thromboembolic events. Two hundred and thirty-four ACS patients undergoing PCI were included in the study, including 171 males (average age = 64.13 ± 12 years) and 63 females (average age = 67.86 ± 10.20 years).

Association between matrix metallopeptidase 1 and type 2 diabetes mellitus coexisting with coronary heart disease in a Han Chinese population

Y. Z. Ma, Jiang, Q. Y., Kong, D. Q., Ma, Y. Z., Jiang, Q. Y., and Kong, D. Q., “Association between matrix metallopeptidase 1 and type 2 diabetes mellitus coexisting with coronary heart disease in a Han Chinese population”, vol. 15, p. -, 2016.

Matrix metallopeptidase 1 (MMP-1) has been reported to be involved in the coexistence of type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD). We sought to examine the association between the MMP-1 gene polymorphism and coexistence of T2DM and CHD in a Han Chinese population. We extracted genomic DNA from the peripheral blood of 794 subjects, including 378 patients with coexisting T2DM and CHD and 416 healthy controls.

Subscribe to Coronary heart disease